Moderna, Inc. (NASDAQ:MRNA) Receives $79.50 Consensus Price Target from Analysts

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) has received a consensus recommendation of "Hold" from the twenty-one brokerages that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $79.50.

A number of research firms have recently commented on MRNA. Needham & Company LLC reiterated a "hold" rating on shares of Moderna in a research note on Friday, November 8th. HSBC raised Moderna from a "hold" rating to a "buy" rating and set a $58.00 price target on the stock in a research report on Monday, November 18th. Jefferies Financial Group reduced their price objective on Moderna from $65.00 to $55.00 and set a "hold" rating for the company in a research report on Tuesday, October 15th. UBS Group dropped their target price on shares of Moderna from $140.00 to $108.00 and set a "buy" rating on the stock in a research report on Thursday, October 24th. Finally, Berenberg Bank initiated coverage on shares of Moderna in a report on Tuesday, November 19th. They issued a "hold" rating and a $42.00 price target for the company.

Moderna Stock Performance

Moderna stock traded down $0.99 during trading hours on Friday, reaching $41.83. 4,850,854 shares of the company were exchanged, compared to its average volume of 4,977,354. Moderna has a 12 month low of $35.80 and a 12 month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock has a 50-day moving average of $48.62 and a 200 day moving average of $85.02. The firm has a market cap of $16.10 billion, a price-to-earnings ratio of -7.19 and a beta of 1.58.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. Moderna's quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.39) EPS. As a group, research analysts anticipate that Moderna will post -9.3 earnings per share for the current year.

Insider Activity at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the firm's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares of the company's stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO James M. Mock sold 715 shares of the business's stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,379 shares of company stock valued at $158,195. 15.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Inspire Trust Co. N.A. increased its position in Moderna by 73.5% during the 3rd quarter. Inspire Trust Co. N.A. now owns 16,525 shares of the company's stock worth $1,104,000 after buying an additional 7,000 shares during the period. Teachers Retirement System of The State of Kentucky boosted its holdings in Moderna by 1.4% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 287,887 shares of the company's stock valued at $19,239,000 after purchasing an additional 3,978 shares during the period. Toronto Dominion Bank grew its position in shares of Moderna by 23.7% during the 3rd quarter. Toronto Dominion Bank now owns 131,477 shares of the company's stock worth $8,787,000 after purchasing an additional 25,177 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Moderna by 2.6% during the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock worth $470,670,000 after purchasing an additional 178,115 shares during the period. Finally, Groupama Asset Managment raised its position in shares of Moderna by 29.1% in the third quarter. Groupama Asset Managment now owns 21,838 shares of the company's stock valued at $1,459,000 after buying an additional 4,920 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.